Brandhorst et al. [38] stated that CD4+-mediated immune responses were a potential biomarker for IBD inflammatory responses because CD4+-mediated immune responses in patients with IBD were significantly enhanced. This evidence concerns the gene CD4 and inflammatory bowel disease.